ArticleAIDS and behavior2023
Acceptance Rate and Reasons for Rejection of Long Acting Injectable Antiretrovirals.
Article in AIDS and behavior, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.
- Willingness to switch to long-acting regimens among people with HIV: a systematic review and meta-analysis.AIDS (London, England) · 2026Pooled it
- HIV Treatment and Program Preferences Among Ryan White Clients in New York City in the Era of Long-Acting Injectable ART: A Discrete Choice Experiment.medRxiv : the preprint server for health sciences · 2026Article
- Optimizing the patient journey: Insights from early implementation of long-acting cabotegravir and rilpivirine in four urban Ryan White-funded clinics in the United States.Journal of the International AIDS Society · 2026Article
- Acceptability, Facilitators, and Barriers of Long-Acting Injectable Cabotegravir/Rilpivirine Among Youth With HIV in the United States.The Journal of adolescent health : official publication of the Society for Adolescent Medicine · 2025Article
- Acceptability of Long-Acting Injectable Antiretroviral Therapy Among People with HIV Receiving Care at Three Ryan White Funded Clinics in the United States.AIDS and behavior · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In January 2021, cabotegravir/rilpivirine, the first extended-release injectable regimen for the treatment of Human Immunodeficiency Virus (HIV) was approved. Long-acting injections have the potential to improve adherence and viral suppression. We analyzed the acceptance rate of, and reasons for declining to switch to, the new regimen. During routine appointments, 102 people living with HIV (PLWH) were presented with information on the new medication and asked if they would like to switch from their current regimen. If they declined to switch, they were asked why. Sixty-nine percent of respondents declined to switch, with frequency of injections as the primary reason. Patients indicated they would be willing to switch if the interval between injections was longer. Forty percent of the patients accepting the injectable anti-retrovirals (ARVs) were not on any other medications. Barriers to switching to long-acting injectable ARVs include the need for more frequent provider visits, aversion to needles, and a perceived lack of evidence supporting the new medication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.